iHateHospitals.com

MEDICAL NEWS: If a trial is adequately powered for two clinically important endpoints, A and B, each of which can fully characterize a treatment benefit to support a regulatory claim by itself, then both endpoints are usually labeled primary, and the trial is deemed positive if either endpoint is statistically significant after a multiplicity [...]

CANCER NEWS: IntroductionPatients with primary operable estrogen receptor negative (ER-) breast (women’s) cancer account for approximately 30% of all cases and generally have worse prognosis (outlook) than ER+ patients. Nevertheless, a significant proportion of ER- cases have favourable outcome and could potentially benefit from a less aggressive course of therapy. Identification of such good [...]

CANCER NEWS: NORWALK, Conn. — The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a clinical trial with the oral immunomodulatory agent pomalidomide (CC-4047) in patients who have received at least two prior therapies including treatments with REVLIMID(R) (lenalidomide) and VELCADE(R) (bortezomib) for Injection. Paul Richardson, MD, Clinical Director of the Jerome [...]

CANCER NEWS: PALO ALTO, Calif. — Telik, Inc. announced today that its novel small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia. The proteasome is an important cellular structure necessary for the growth and function of cancer cells and inhibition of the proteasome [...]

CANCER NEWS: Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, announced publication of a Phase 1 clinical study(1) on its BiTE(R) antibody blinatumomab (MT103/MEDI-538) in this week’s issue of Science. The article is available at www.sciencemag.org. Blinatumomab is being co-developed with MedImmune. Blinatumomab is [...]

CANCER NEWS: According to a study from the United States, “Metastatic disease is present in up to 20% of patients at the time of diagnosis (finding out what’s wrong) of colorectal cancer. The most frequently involved sites are the liver and the lungs.A rare form of lung metastatic disease is endobronchial metastases, most commonly [...]

CANCER NEWS: According to a study from the United States, “Metastatic disease is present in up to 20% of patients at the time of diagnosis (finding out what’s wrong) of colorectal cancer. The most frequently involved sites are the liver and the lungs.A rare form of lung metastatic disease is endobronchial metastases, most commonly [...]

MEDICAL NEWS: This article presents a new approach to the problem of deriving an optimal design for a randomized group sequential clinical trial based on right-censored event times. We are motivated by the fact that, if the proportional hazards assumption is not met, then a conventional design’s actual power can differ substantially from its [...]

(Mesothelioma News) BOTHELL, WA and VANCOUVER — OncoGenex Pharmaceuticals announced today that OGX-011, also known as custirsen sodium, received Fast Track designation from the U.S. Food & Drug Administration (FDA) in combination with docetaxel for progressive metastatic prostate cancer. OGX-011 is currently completing five Phase 2 clinical studies in prostate, lung and breast cancer, and [...]

(Mesothelioma News) The biotech company that Justin Murdock, the son of Dole Food Co. owner David Murdock, leads has begun stage-III clinical trials for a lung cancer vaccine. NovaRx, based in San Diego, is testing its Lucanix vaccine in about 700 patients with lung cancer — a disease which the American Cancer Society says is [...]

DRUGS & RX: ANTONY, France, August 27, 2008 /PRNewswire-FirstCall/ –
- Oralair(R) Grasses 300IR Highly Positive Clinical Results in a Pharmacodynamic Study Conducted in an Allergen Challenge Chamber
Stallergenes S.A. announces the highly positive results of a…

View the source of this article…

Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber was another [...]

DRUGS & RX: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug 27, 2008 - Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing next generation proprietary targeted medicines for cancer treatment, today announced the publication of preclinical data…

View the source of this article…

Curis Announces Nature Publication Elucidating a Paracrine Mechanism of Action in Hedgehog-Expressing Tumors was another wonderful [...]